Sheila A Doggrell

Summary

Country: Australia

Publications

  1. ncbi request reprint Celecoxib to prevent restenosis--results from the COREA-TAXUS trial
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:339-41. 2008
  2. ncbi request reprint Is sapropterin treatment suitable for all subjects with phenylketonuria?
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:145-7. 2008
  3. ncbi request reprint Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 14 Quandong Cresent, Nightcliff, NT 0810, Australia
    Curr Opin Investig Drugs 8:742-9. 2007
  4. ncbi request reprint Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:1619-22. 2008
  5. ncbi request reprint Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 41 Summerhill Rd, Reservoir, VIC 3073, Australia
    Expert Opin Pharmacother 8:2903-15. 2007
  6. ncbi request reprint Is rimonabant efficacious and safe in the treatment of obesity?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:2727-31. 2008
  7. ncbi request reprint Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
    Sheila A Doggrell
    Doggrell Biomedical Communications, School of Biomedical Sciences, University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 14:339-42. 2005
  8. ncbi request reprint The therapeutic potential of dopamine modulators on the cardiovascular and renal systems
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 11:631-44. 2002
  9. ncbi request reprint Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats
    Sheila A Doggrell
    Cardiovascular Pharmacology Group, Faculty of Medicine and Health Science, The University of Auckland, New Zealand
    J Pharm Pharmacol 54:707-15. 2002
  10. ncbi request reprint Conivaptan Yamanouchi
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Curr Opin Investig Drugs 6:317-26. 2005

Collaborators

  • Ying Yu Chen

Detail Information

Publications46

  1. ncbi request reprint Celecoxib to prevent restenosis--results from the COREA-TAXUS trial
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:339-41. 2008
    ..In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use...
  2. ncbi request reprint Is sapropterin treatment suitable for all subjects with phenylketonuria?
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:145-7. 2008
    ..In summary, sapropterin effectively reduces blood phenylalanine levels in a small proportion of subjects with phenylketonuria...
  3. ncbi request reprint Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 14 Quandong Cresent, Nightcliff, NT 0810, Australia
    Curr Opin Investig Drugs 8:742-9. 2007
    ..Aquaretics are useful in the treatment of edema/hyponatremia which ultimately occurs in end-stage heart failure, liver cirrhosis and the syndrome of inappropriate secretion of antidiuretic hormone...
  4. ncbi request reprint Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:1619-22. 2008
    ..Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer...
  5. ncbi request reprint Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 41 Summerhill Rd, Reservoir, VIC 3073, Australia
    Expert Opin Pharmacother 8:2903-15. 2007
    ..Thus, it may be premature to recommend varenicline for smoking cessation in preference to bupropion...
  6. ncbi request reprint Is rimonabant efficacious and safe in the treatment of obesity?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:2727-31. 2008
    ..Orlistat and sibutramine are the drugs used at present for weight loss, but they both have a relatively modest effect...
  7. ncbi request reprint Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
    Sheila A Doggrell
    Doggrell Biomedical Communications, School of Biomedical Sciences, University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 14:339-42. 2005
  8. ncbi request reprint The therapeutic potential of dopamine modulators on the cardiovascular and renal systems
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 11:631-44. 2002
    ..One priority is an orally-active selective dopamine D1 receptor agonist...
  9. ncbi request reprint Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats
    Sheila A Doggrell
    Cardiovascular Pharmacology Group, Faculty of Medicine and Health Science, The University of Auckland, New Zealand
    J Pharm Pharmacol 54:707-15. 2002
    ..However, as the positive inotropic effect is not observed with clinically relevant concentrations at a physiological rate in heart failure, dofetilide is unlikely to be useful as a positive inotrope in the treatment of heart failure...
  10. ncbi request reprint Conivaptan Yamanouchi
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Curr Opin Investig Drugs 6:317-26. 2005
    ..In January 2004, Yamanouchi submitted an NDA in the US for injectable conivaptan for the treatment of hyponatremia and, in December 2004, the FDA issued approval, although additional safety data were requested...
  11. ncbi request reprint CHARMed - the effects of candesartan in heart failure
    Sheila A Doggrell
    The University of Queensland, School of Biomedical Sciences, Australia
    Expert Opin Pharmacother 6:513-6. 2005
  12. ncbi request reprint Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 14:655-69. 2005
    ..An ibutilide analogue, trecetilide, requires further investigation but may offer a less readily metabolised and pro-arrhythmic alternative to ibutilide...
  13. ncbi request reprint Which drug combination for hormone-refractory prostate cancer?
    Sheila A Doggrell
    The University of Queensland, School of Biomedical Sciences, QLD 4072, Australia
    Expert Opin Pharmacother 6:667-70. 2005
    ..With the present information, there is little to distinguish between these combinations...
  14. ncbi request reprint NF-kappa B--a target in the inflammation of bone destruction
    Sheila A Doggrell
    University of Queensland, School of Biomedical Sciences, Australia
    Expert Opin Ther Targets 9:191-3. 2005
  15. ncbi request reprint Taking the 20-HETE out of the cardiovascular system: the potential of 20-HETE synthesis inhibitors
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology Akoranga Campus, Auckland, New Zealand
    Curr Opin Investig Drugs 6:901-6. 2005
    ..However, 20-HETE synthase inhibitors can have cardioprotective and cerebroprotective effects in animal models, and can inhibit angiogenesis; therefore they may have clinical potential in these areas...
  16. ncbi request reprint BG-9928 (Biogen Idec)
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology Akoranga Campus, Auckland, New Zealand
    Curr Opin Investig Drugs 6:962-8. 2005
    ..Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing...
  17. ncbi request reprint Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology Akoranga Campus, Northcote, Auckland, New Zealand
    Expert Opin Pharmacother 6:2141-4. 2005
  18. ncbi request reprint Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus
    Sheila A Doggrell
    Charles Darwin University, School of Science, Casuarina, NT 0811, Australia
    Expert Opin Ther Targets 10:627-30. 2006
  19. ncbi request reprint Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
    Sheila A Doggrell
    School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia
    Expert Opin Pharmacother 7:2169-73. 2006
    ..In COMBINE, this percentage was high in the group having medical management and placebo pills, and naltrexone or additional behavioural therapy only had modest additional effects...
  20. ncbi request reprint Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats
    Sheila A Doggrell
    Cardiovascular Pharmacology Group, Faculty of Medicine and Health Sciences, The University of Auckland, Private Bag 92109, Auckland, New Zealand
    J Pharm Pharmacol 54:1407-12. 2002
    ..These functional differences in beta1- and beta2-adrenoceptor-mediated responses of the left and right atria of pre-hypertensive SHRs cannot be caused by hypertension, and may be associated with the onset of hypertension...
  21. ncbi request reprint The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
    Sheila A Doggrell
    Expert Opin Pharmacother 9:875-8. 2008
    ..Torcetrapib was spectacularly withdrawn in December 2006, when a Phase III clinical trial showed increased cardiovascular adverse events...
  22. ncbi request reprint Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology, Northcote, Auckland, New Zealand
    Rev Recent Clin Trials 1:143-53. 2006
    ..Alternatively, atorvastatin can be used in combination with a fibrate to increase HDL-cholesterol in patients with diabetes/metabolic syndrome...
  23. ncbi request reprint Recent findings with docetaxel in postoperative treatment for breast cancer
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology, Akoranga Campus, Northcote, Auckland, New Zealand
    Expert Opin Pharmacother 6:2903-6. 2005
  24. ncbi request reprint Tolvaptan (Otsuka)
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Curr Opin Investig Drugs 5:977-83. 2004
    ..Otsuka is developing tolvaptan (OPC-41061), an orally active non-peptide vasopressin V2 antagonist, as a diuretic for the potential treatment of congestive heart failure. By November 2003, tolvaptan was undergoing phase III clinical trials...
  25. ncbi request reprint Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis
    Sheila A Doggrell
    University of Queensland, School of Biomedical Sciences, Australia
    Expert Opin Pharmacother 5:2209-20. 2004
    ..The results of the REALITY trial comparing the sirolimus- and paclitaxel-eluting stents in diabetics and other high-risk patients are eagerly awaited...
  26. ncbi request reprint Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Rev Cardiovasc Ther 2:745-52. 2004
    ..To date, paclitaxel is showing promise as an eluting agent to prevent restenosis associated with stenting...
  27. ncbi request reprint Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 12:1855-9. 2003
    ..5% in the placebo group and 26% in the AGI-1067 group. The lumen area of reference segments was reduced in the placebo group but increased with the higher doses of AGI1067. Unlike probucol, AGI-1067 did not alter QTc interval...
  28. ncbi request reprint ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease
    Sheila A Doggrell
    School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 4:1185-8. 2003
    ..Combination treatment should be considered in non-diabetic renal disease especially if the disease is progressing with ACE treatment alone...
  29. ncbi request reprint The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation
    Sheila A Doggrell
    School of Biomedical Sciences, University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 12:805-23. 2003
    ..In hypertension, agonists at the 5-HT(7) and antagonists at the 5-HT(2B) may reduce blood pressure, and in diabetes, sarpogrelate may protect against nephropathy...
  30. ncbi request reprint Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction
    Sheila A Doggrell
    School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 4:587-90. 2003
    ....
  31. ncbi request reprint ACE inhibitors or AT-1 antagonists - which is OPTIMAAL after acute myocardial infarction?
    Sheila A Doggrell
    School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 4:407-9. 2003
    ..In conclusion, if tolerated, captopril should remain the preferred treatment for patients after complicated acute myocardial infarction...
  32. ncbi request reprint The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 11:1537-52. 2002
    ....
  33. ncbi request reprint TACE inhibition: a new approach to treating inflammation
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 11:1003-6. 2002
    ..Further longer-term studies of GW3333 in animal models are required to determine whether its benefit is maintained. TACE inhibition may represent a new approach to treating inflammation...
  34. ncbi request reprint Present and future pharmacotherapy for heart failure
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 3:915-30. 2002
    ..Small clinical trials with recombinant growth hormone to thicken ventricles in dilated cardiomyopathy have given variable results...
  35. ncbi request reprint Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Pharmacother 5:205-8. 2004
    ....
  36. ncbi request reprint The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 13:69-72. 2004
    ..Thus, the activation of somatostatinergic neurotransmission, with FK960 or a similar drug, has considerable potential in the treatment of cognitive impairment...
  37. ncbi request reprint Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?
    Sheila A Doggrell
    Doggrell Biomedical Communications, Auckland, New Zealand
    Expert Opin Investig Drugs 13:161-3. 2004
    ..A follow-up study is necessary to determine whether these effects translate into the important end points of reduced incidences of death, graft loss or a second transplantation...
  38. ncbi request reprint Dawn of Aurora kinase inhibitors as anticancer drugs
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 13:1199-201. 2004
    ..In nude mice, VX-680 markedly reduced human AML tumours. The development of VX-680 for use in AML should continue...
  39. ncbi request reprint After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia
    Sheila A Doggrell
    School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 5:1957-64. 2004
    ..Further trials are necessary in order to determine whether doxazosin GITS is superior to other alpha1-adrenoceptor antagonists in BPH...
  40. ncbi request reprint Recent important clinical trials of drugs in osteoporosis
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Pharmacother 5:1635-8. 2004
    ..As hypercalcaemia is a relatively common adverse effect with calcitriol in the treatment of secondary osteoporosis, requiring monitoring of calcium levels, alendronate is the easier agent to use...
  41. ncbi request reprint Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Pharmacother 5:1431-4. 2004
    ....
  42. ncbi request reprint Urotensin-II and the cardiovascular system--the importance of developing modulators
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 13:479-87. 2004
    ..Peptide and non-peptide agonists and antagonists of the U-II receptor are being developed and will be useful in the characterisation of the effects of U-II, and may have some therapeutic potential...
  43. ncbi request reprint Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia
    Sheila A Doggrell
    Doggrell Biomedical Communications, Lynfield, Auckland, New Zealand
    Expert Opin Pharmacother 5:1209-11. 2004
    ..One interpretation of these results is that if finasteride is effective alone in BPH, the combination with an alpha 1 -adrenoceptor antagonist will give an additive effect...
  44. ncbi request reprint Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
    Sheila A Doggrell
    Doggrell Biomedical Communications, Auckland, New Zealand
    Expert Opin Investig Drugs 13:431-4. 2004
    ..Vasopressin receptor type 2 antagonists should proceed to clinical trial for these polycystic kidney diseases...
  45. ncbi request reprint Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
    Sheila A Doggrell
    Doggrell Biomedical Communications, Auckland, New Zealand
    Expert Opin Pharmacother 5:955-8. 2004
    ..The combination of alendronate and PTH does not have greater benefit than either agent alone, and may even be detrimental, thus should not be used...
  46. ncbi request reprint Responsiveness, affinity constants and beta-adrenoceptor reserves for isoprenaline on aortae from normo-, pre- and hypertensive rats
    Ying Yu Chen
    Cardiovascular Pharmacology Group, Faculty of Medicine and Health Science, The University of Auckland, New Zealand
    J Pharm Pharmacol 54:515-22. 2002
    ..There are no changes in affinity, but major changes in the sensitivity, maximum responses and aortic beta2-adrenoceptor reserves to isoprenaline in the maturation of normotensive and pre-hypertensive aortae...